Therapy (HBV)
Interferon Retreatment Useful in HBeAg+ Disease
Published in Hepatitis Weekly, August 23rd, 1999
Treatment with interferon alpha (IFN-(alpha)) has been shown to result in sustained loss of hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) in between 25 percent to 40 percent of HBV positive patients.
More than half of HBV patients treated with IFN-(alpha), however, either do not achieve a response or relapse after initially responding. It is unclear whether these patients benefit from another cycle of IFN-(alpha).
"Attempts in pilot studies of retreatment with IFN-(alpha) for previous...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1999-08-23)
More Articles from Hepatitis Weekly
- Therapy (HBV)
L528M Mutation is Risk Factor for Nucleoside Breakthrough - Coinfection (HCV/HGV)
Dual HCV/HGV Infection Low in Asian Study - Coinfection (HCV/TTV)
IFN Does Not Influence TTV Levels in HCV+ - Controversies (Pediatrics)
Infant HBV Vaccination Debated in Congressional Hearing - Non-Hodgkin's Lymphoma (Etiology)
Link Between HCV and NHL Examined - Interferon Therapy
Immune Response Not Related to IFN Efficacy - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
